Semaglutide vs. Tirzepatide — A Physician's Honest Comparison

The most common question I get from prospective patients is some version of this: "Which one should I take?"

It's a fair question. The GLP-1 medication category has expanded quickly, the brand names are confusing, and most people are trying to make a decision based on what they've read on social media or heard from a friend. So let me give you the actual physician answer — not a marketing pitch for either drug.

But first, a piece of history most people don't know.

GLP-1 Medications Have Been Around Longer Than You Think

GLP-1 receptor agonists have existed in various forms for roughly a decade. They are not new science. What changed the game was the development of a formulation that could last a full week in the body — allowing for a once-weekly injection instead of daily dosing. That breakthrough made the medications dramatically more practical for real-world use.

Here's the part that tends to surprise people: early research into long-acting GLP-1 compounds was influenced by studying the saliva of the Gila monster — a venomous lizard native to the American Southwest. The Gila monster produces a compound called exendin-4 that mimics GLP-1 activity and persists in the body far longer than the human version. That biological quirk pointed researchers toward the long-acting formulations we use today.

Not the origin story most patients expect. But it's a good illustration of where medical breakthroughs actually come from.

Semaglutide: The First-Generation Standard

Semaglutide — sold under brand names Ozempic and Wegovy, and available as compounded semaglutide through licensed pharmacies — is the more established option. It works by activating the GLP-1 receptor, which slows gastric emptying, reduces appetite, and helps regulate blood sugar.

The clinical data is strong. Weight loss of 10 to 15 percent of body weight over the course of treatment is well-documented. Cardiovascular benefits have been demonstrated in large trials. For most patients who are appropriate candidates, semaglutide is an excellent starting point.

Its advantages are real: it is the lower-cost option among compounded GLP-1s, the clinical track record is longer, and the majority of patients tolerate it well.

Its limitations are also real. GI side effects — nausea, constipation, slowed digestion — are the most common reason patients struggle with it. For most people these are manageable, particularly when dose escalation is handled carefully. But for patients with pre-existing GI conditions, semaglutide requires serious caution. I would not initiate it in a patient with active gastroparesis, severe GERD, Crohn's disease, or ulcerative colitis without a thorough risk-benefit conversation and close monitoring.

Tirzepatide: The Second-Generation Dual-Action Option

Tirzepatide — sold as Mounjaro and Zepbound, and available as compounded tirzepatide — is a newer class of medication. It is what's called a dual agonist: it activates both the GLP-1 receptor and the GIP receptor. GIP is a second gut hormone involved in appetite regulation and metabolic function.

Activating two pathways instead of one produces meaningfully different results in clinical trials. Tirzepatide has demonstrated greater average weight loss than semaglutide in head-to-head comparisons. The GI side effect profile, while similar in character, appears somewhat better tolerated by many patients — likely due to the GIP mechanism balancing some of the GI effects of GLP-1 stimulation alone.

Tirzepatide is the stronger tool. For patients with more significant metabolic resistance, higher starting weight, or who have had limited response to semaglutide, it is often the appropriate first choice. The same GI cautions apply — gastroparesis, severe reflux, inflammatory bowel disease all require careful evaluation before initiating either medication.

The Question Nobody Asks — But Should

Most patients come in asking which medication is better. The more important question is: how are you planning to escalate the dose?

The majority of GI side effects — and the majority of patients who stop these medications prematurely — are the result of dose escalation that moves too fast. The clinical trials studied the highest doses because that is what produces the most dramatic weight loss data. But the highest dose is not the goal. The lowest effective dose is always the right target.

I have seen patients pushed to maximum doses in 8 to 10 weeks who couldn't eat, couldn't function, and quit. I have seen patients maintained at lower doses who lost 18 percent of their body weight over a year and kept it off. The data does not care about speed. Your body does not care about speed. What matters is a titration protocol that your physiology can actually tolerate — and sustain.

Losing 50 pounds in six months is not a success story if you gain 40 of it back the month after stopping. That's a sales metric, not a clinical outcome.

So Which One Is Right for You?

The honest answer: it depends on your clinical profile, your GI history, your degree of metabolic resistance, and your goals. There is no universal right answer. There is only the right answer for your specific body — determined by a physician who has actually reviewed your history.

As a general framework:

Semaglutide is a strong starting point for most patients — lower cost, well-established, effective for the majority of appropriate candidates.

Tirzepatide is worth considering for patients who need stronger appetite suppression, have had limited results with semaglutide, or have higher weight loss goals with good GI tolerance.

Neither medication is appropriate without a structured program around it — proper hydration, adequate protein, strength training, and a dose escalation strategy designed for the long game.

The Medication Is the Tool. The Program Is the Work.

GLP-1 medications are the most effective pharmacological tools we have ever had for metabolic health. They are genuinely remarkable. But a tool without a structured approach produces temporary results.

At Summit, every patient gets a physician-designed framework — the Ten Commandments of GLP-1 — alongside their medication. Because the patients who do best are not the ones who got the highest dose fastest. They are the ones who used the medication as a window of opportunity to build a different metabolic foundation.

That is the program Summit was built to deliver.

If you'd like a physician to actually evaluate which option makes sense for your situation, applications take less than five minutes. Dr. Miranda personally reviews every case.

→ Apply at summitmetabolichealth.com/apply